Fevipiprant
Fevipiprant (INN; code name QAW039) is a drug being developed by Novartis which acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2 or CRTh2). As of 2016, it is in Phase II clinical trials for the treatment of asthma.
Wikipage redirect
primaryTopic
Fevipiprant
Fevipiprant (INN; code name QAW039) is a drug being developed by Novartis which acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2 or CRTh2). As of 2016, it is in Phase II clinical trials for the treatment of asthma.
has abstract
Fevipiprant (INN; code name QA ...... s for the treatment of asthma.
@en
ATC prefix
CAS number
872365-14-5
FDA UNII code
2PEX5N7DQ4
IUPAC name
{2-methyl-1-[4-(methylsulfonyl ...... 2,3-b]pyridin-3-yl}acetic acid
@en
PubChem
thumbnail
Wikipage page ID
51,257,095
Wikipage revision ID
736,447,315
bioavailability
Unaffected by food
ChemSpiderID
23,582,412
elimination half-life
excretion
legal status
Investigational
metabolism
Hepatic glucuronidation
molecular weight
routes of administration
smiles
StdInChIKey
GFPPXZDRVCSVNR-UHFFFAOYSA-N
comment
Fevipiprant (INN; code name QA ...... s for the treatment of asthma.
@en
label
Fevipiprant
@en
